NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) — atai Life Sciences NV ATAI (“atai”), a clinical-stage biopharmaceutical company committed to transforming the treatment of mental disorders, will participate in the following investor conferences in September:
- Citis 17th Annual BioPharma Conference in Boston
Format: industry panel
Date and time: Wednesday 7 Septemberth10:30 a.m. ET – 11:15 a.m. ET
Conference link: URL
- HC Wainwright’s 24thth Annual global investment conference in New York City
Format: company presentation
Date and time: Tuesday 13 Septemberth11:00 a.m. ET – 11:45 a.m. ET
Conference link: URL
- Cowen’s 2ndnd Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
Format: industry panel
Date and time: Monday 19 Septemberth, 3:05 p.m. ET – 4:05 p.m. ET | 4:15 p.m. ET – 5:15 p.m. ET
Conference link: URL
- Jefferies’ 1St Annual Summit on Psychedelics/Emerging Novel Treatments for Mental Health in New York City
Format: company presentation
Date and time: Thursday 22 Septembernd9:30 a.m. ET – 10:15 a.m. ET
Link: TBA
The presentations and archived webcasts will also be available on the events Section of the Atai website where they are available for up to 90 days.
About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company committed to transforming the treatment of mental health disorders. Founded in 2018 in response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to sourcing, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction and other mental disorders.
By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines within its companies to achieve clinically meaningful and sustainable behavioral changes in mental health patients.
atai’s vision is to heal mental disorders so everyone, everywhere, can live a more fulfilling life. For more…
